Nathaniel J Martin, Christoph G S Nabzdyk, Scott D Nei, Andrew N Rosenbaum, Troy G Seelhammer, Patrick M Wieruszewski
{"title":"Impella purge solutions in patients receiving extracorporeal membrane oxygenation.","authors":"Nathaniel J Martin, Christoph G S Nabzdyk, Scott D Nei, Andrew N Rosenbaum, Troy G Seelhammer, Patrick M Wieruszewski","doi":"10.1007/s10047-026-01595-2","DOIUrl":null,"url":null,"abstract":"<p><p>The optimal Impella purge solution in patients receiving concomitant ECMO and Impella (ECPELLA) support remains to be elucidated. We aimed to assess Impella device function in patients supported by ECPELLA receiving heparin-containing or anticoagulant-free (5% dextrose or sodium bicarbonate) purge solutions. Of 25 included patients, 14 received anticoagulant-free and 11 received heparin-containing purge solutions, with a median of five days of ECPELLA support. The only episode of Impella device malfunction occurred in the heparin-containing group. Given the low event rate and apparent maintenance of acceptable device longevity, use of anticoagulant-free purge solutions alongside systemic anticoagulation in ECPELLA patients may be reasonable but requires validation in an appropriately powered study.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":"29 4","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Artificial Organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10047-026-01595-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
The optimal Impella purge solution in patients receiving concomitant ECMO and Impella (ECPELLA) support remains to be elucidated. We aimed to assess Impella device function in patients supported by ECPELLA receiving heparin-containing or anticoagulant-free (5% dextrose or sodium bicarbonate) purge solutions. Of 25 included patients, 14 received anticoagulant-free and 11 received heparin-containing purge solutions, with a median of five days of ECPELLA support. The only episode of Impella device malfunction occurred in the heparin-containing group. Given the low event rate and apparent maintenance of acceptable device longevity, use of anticoagulant-free purge solutions alongside systemic anticoagulation in ECPELLA patients may be reasonable but requires validation in an appropriately powered study.
期刊介绍：
The aim of the Journal of Artificial Organs is to introduce to colleagues worldwide a broad spectrum of important new achievements in the field of artificial organs, ranging from fundamental research to clinical applications. The scope of the Journal of Artificial Organs encompasses but is not restricted to blood purification, cardiovascular intervention, biomaterials, and artificial metabolic organs. Additionally, the journal will cover technical and industrial innovations. Membership in the Japanese Society for Artificial Organs is not a prerequisite for submission.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
